Prostate cancer research: tools, cell types, and molecular targets

Area of Science:

• Oncology
• Molecular Biology
• Cancer Cell Biology

Background:

• Prostate tumors exhibit heterogeneity, comprising luminal-like adenocarcinoma and less differentiated, stem-like non-adenocarcinoma and small cell carcinoma.
• Dedifferentiation from luminal-like to stem-like phenotypes is driven by stem cell transcription factors (scTF) like LIN28A, NANOG, POU5F1, and SOX2, leading to β2-microglobulin (B2M) downregulation.

Purpose of the Study:

• To investigate the role of stromal signaling, specifically proenkephalin (PENK), in regulating prostate cancer cell differentiation.
• To explore therapeutic strategies targeting distinct prostate cancer cell types, including stem-like and adenocarcinoma cells.

Main Methods:

• Investigated the effect of PENK on scTF and B2M expression in stem-like small cell carcinoma LuCaP 145.1 cells.
• Utilized scTF and PENK transfection to induce dedifferentiation and differentiation in prostate cancer cells.
• Examined extracellular anterior gradient 2 (eAGR2) as a targetable adenocarcinoma antigen.

Main Results:

• PENK treatment downregulated scTF and upregulated B2M in stem-like cells, indicating a shift towards differentiation.
• Prostate cancer cells could be reprogrammed to a dedifferentiated state by scTF transfection and subsequently differentiated by PENK transfection.
• Extracellular AGR2 (eAGR2) is identified as a cancer-specific antigen on differentiated adenocarcinoma cells, while stem-like cells are AGR2-negative.

Conclusions:

• PENK acts as a differentiation-inducing factor for stem-like prostate cancer cells by modulating scTF and B2M.
• Targeting scTF with factors like PENK presents a potential differentiation therapy for AGR2-negative, stem-like prostate cancers.
• Therapeutic strategies should consider the distinct cell types within prostate tumors, leveraging antigens like eAGR2 for adenocarcinoma and PENK for stem-like cells.